We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Novel Method Described for Blocking Action of Cancer-Promoting MicroRNA

By LabMedica International staff writers
Posted on 08 Aug 2016
A team of molecular biologists has described a novel method for selectively blocking the activity of a cancer-promoting microRNA.

MicroRNAs (miRNAs) are a small noncoding family of 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. More...
Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.

In order to block the activity of the miRNA miR-21, which is present in high levels in many tumors where it increases the expression of cancer-promoting genes and decreases cancer suppressors, investigators at the University of Washington (Seattle, USA) manipulated the specificity of the RNA recognition motif (RRM) of the protein Rbfox2 (RNA binding protein, fox-1 homolog 2). They did this by engineering the conserved RRM of the Rbfox2 protein to specifically bind to the terminal loop of the microRNA precursor (pre-miR-21) with high affinity.

The modified pre-miR-21 could not be processed by the enzyme Dicer. Dicer, which is encoded by the DICER1 gene, trims double stranded RNA, to form small interfering RNA (siRNA) or microRNA (miRNA). These processed RNAs are incorporated into the RNA-induced silencing complex (RISC), which targets messenger RNA to prevent translation.

In a separate series of experiments the investigators attached the miR-21 binding regions of Rbfox2 onto the Dicer enzyme. This hybrid Rbfox2-Dicer protein sliced miR-21 into inactive fragments. Results published in the July 18, 2016, online edition of the journal Nature Chemical Biology revealed that the hybrid enzyme degraded pre-miR-21 specifically in vitro and suppressed mature miR-21 levels in cells, which resulted in increased expression of the tumor suppressor PDCD4 and significantly decreased viability for cancer cells.

"What we show here is a proving ground - a process to determine how to make the correct changes to proteins," said senior author Dr. Gabriele Varani, professor of chemistry at the University of Washington. "This method relies on knowledge of high-quality structures. That allowed us to see which alterations would change binding to the microRNA target."

Related Links:
University of Washington



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.